Boston Partners Lowers Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Boston Partners cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 407,984 shares of the biopharmaceutical company’s stock after selling 163,963 shares during the period. Boston Partners owned about 0.32% of Halozyme Therapeutics worth $19,955,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in HALO. GSA Capital Partners LLP acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $217,000. CIBC Asset Management Inc purchased a new stake in shares of Halozyme Therapeutics during the third quarter worth $211,000. Natixis Advisors LLC raised its stake in shares of Halozyme Therapeutics by 86.7% in the third quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company’s stock valued at $6,958,000 after acquiring an additional 56,461 shares in the last quarter. Quest Partners LLC boosted its holdings in Halozyme Therapeutics by 1,386.0% in the third quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 9,134 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Halozyme Therapeutics during the 3rd quarter worth $1,899,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $64.32 on Friday. The company has a fifty day moving average of $57.95 and a two-hundred day moving average of $54.75. The company has a market capitalization of $7.92 billion, a PE ratio of 18.75, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HALO shares. Benchmark reiterated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the sale, the director now owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,697 shares of company stock worth $1,754,451. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.